SCHEDULE: FMR LLC Discloses 15.6% Stake in 10x Genomics

FMR LLC and Abigail P. Johnson reported a beneficial ownership of 15.6% of 10x Genomics, Inc.'s Class A Common Stock as of February 27, 2026.

Summary

• FMR LLC and Abigail P. Johnson beneficially own an aggregate of 18,543,561.62 shares of 10x Genomics, Inc. Class A Common Stock.
• This ownership represents 15.6% of the outstanding Class A Common Stock of 10x Genomics, Inc.
• The reported beneficial ownership includes 892,772 shares of Class B Common Stock, which are convertible into Class A Common Stock on a 1:1 basis.
• These included Class B shares represent 8.8579% of the total outstanding Class B Common Stock.
• Assuming the conversion of all outstanding Class B Common Stock into Class A Common Stock, the reported beneficial ownership would represent 14.5153% of the outstanding Class A Common Stock.
• FMR LLC holds sole voting power over 18,506,782.00 shares and sole dispositive power over 18,543,561.62 shares.
• Abigail P. Johnson holds sole dispositive power over 18,543,561.62 shares.
• This filing is an Amendment No. 14 to a Schedule 13G, indicating an update to previously reported beneficial ownership.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the continued significant beneficial ownership by a major institutional investor like FMR LLC suggests ongoing confidence in 10x Genomics, Inc.

Positives

• The continued significant beneficial ownership by FMR LLC, a major institutional investment manager, signals ongoing confidence in 10x Genomics, Inc.

Negatives

• No specific negative information regarding 10x Genomics, Inc.'s operations or financial performance is contained within this beneficial ownership report.

Risks

• No specific risks related to 10x Genomics, Inc.'s business or financial health are disclosed in this beneficial ownership report.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant institutional ownership by firms like FMR LLC in the biotechnology and genomics sector, represented by 10x Genomics, often reflects long-term confidence in the company's market position and growth potential, aligning with broader trends of investment in life sciences innovation.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and stability.
• Investment Community: Offers insight into the holdings of a major institutional investor in 10x Genomics, Inc.

Key Dates

Keywords

10x Genomics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Class A Common Stock, Institutional Investor, Biotechnology, Genomics, Fidelity